Otsuka opts for majority JV as it links with Claris for IV products
This article was originally published in Scrip
Executive Summary
Following negotiations reported by Scrip earlier this week (scripintelligence.com, 4 December 2012), Otsuka Holdings has now announced a definitive agreement with India's Claris Lifesciences for a business tie-up in the area of intravenous solutions and clinical nutrition products.
You may also be interested in...
Fosun Pitches for India's Gland
Shanghai Fosun Pharmaceutical Group Co. Ltd. has confirmed it interest in the Indian injectables firm, Gland Pharma Ltd., underscoring how differentiated niche plays continue to attract buyer interest.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.